
Table of Contents

Product details.....	2
1. Introduction.....	7
2. Worldwide Marketing Approval Status	8
3. Actions Taken in the Reporting Period for Safety Reasons.....	9
4. Changes to Reference Safety Information.....	9
5. Inventory of Clinical Trials Ongoing and Completed During the Reporting Period	9
6. Estimated cumulative Exposure	10
6.1 Cumulative Subject Exposure in the Development Programme	10
6.2 Patient Exposure from Marketing Experience	10
7. Data in Line Listings and Summary Tabulations.....	10
7.1 Reference Information.....	11
7.2 Line Listings of Serious Adverse Reactions during the Reporting Period	11
7.3 Cumulative Summary Tabulations of Serious Adverse Events	12
8. Significant Findings from Clinical Trials During the Reporting Period.....	13
8.1 Completed Clinical Trials.....	13
8.2 Ongoing Clinical Trials	23
8.3 Long-term Follow-up	24
8.4 Other Therapeutic Use of Investigational Drug	24
8.5 New Safety Data related to Combination Therapies	24
9. Safety findings from Non-Interventional Studies.....	24
10. Other Clinical Trial/Study Safety Information	24
11. Safety Findings from Marketing Experience.....	24
12. Non-clinical data.....	25
13. Literature.....	25
14. Other DSURs	26
15. Lack of Efficacy.....	26
16. Region –Specific Information.....	26

16.1	Cumulative summary tabulation of serious adverse reactions	26
16.2	List of subjects who died during the reporting period.....	26
16.3	List of subjects who dropped out of clinical trials in association with an adverse event during the reporting period	26
16.4	Significant Phase I protocol modifications.....	27
16.5	Significant manufacturing changes	27
16.6	Description of the general investigation plan for the coming year	27
16.7	Log of outstanding business with respect to the US IND	27
17.	Late-Breaking Information	27
18.	Overall Safety Assessment	27
18.1	Evaluation of the Risks.....	28
18.1.1	Newly identified safety issues	28
18.1.2	Previously identified reactions	28
18.1.3	Clinically significant toxicities.....	28
18.1.4	Deaths	28
18.1.5	Study drug discontinuations	28
18.1.6	Interactions	28
18.1.7	Non-clinical safety findings	28
18.1.8	Manufacturing issues.....	29
18.1.9	Lack of efficacy.....	29
18.1.10	Special populations.....	29
18.1.11	Pregnancy and lactation.....	29
18.1.12	Long-term treatment.....	29
18.1.13	Medication errors.....	29
18.1.14	Patient compliance.....	29
18.1.15	Overdose.....	29
18.1.16	Drug misuse and abuse.....	30
18.1.17	Protocol procedures	30
18.1.18	Drug Class	30
18.2	Benefit-Risk Considerations.....	30
19.	Summary of important risks	30
20.	Conclusions.....	30
	Appendices	31